- Jul 2, 2003
- 5,990
- 1,023
Hydroxychloroquine - was taken by the President he stated many times.. So according to this article Remdesivir is less likely to be effective.
===============================================
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that Remdesivir is not an approved treatment for coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, but rather, is being investigated for and is currently available under an FDA emergency use authorization (EUA) for the treatment of severe COVID-19 in hospitalized patients. ========================================================You should not take chloroquine or hydroxychloroquine while you are taking remdesivir. Either of these other medicines could make remdesivir less effective.
A negative COVID-19 test does not mean recovery
Pandemic policy must include defining and measuring what we mean by mild infection.
www.nature.com
A negative COVID-19 test does not mean recovery
===============================================
Remdesivir Side Effects: Common, Severe, Long Term - Drugs.com
Learn about the potential side effects of remdesivir. Includes common and rare side effects information for consumers and healthcare professionals.
www.drugs.com
Side effects include:
Randomized, double-blind, placebo-controlled trial in hospitalized adults with severe COVID-19 in China: Adverse events (e.g., constipation, hypoalbuminemia, hypokalemia, anemia, thrombocytopenia, increased total bilirubin concentrations) reported in 66 or 64% of patients who received remdesivir or placebo, respectively.
Serious adverse events reported in 18 or 26%, respectively, and drug discontinued because of adverse events in 12 or 5%, respectively.
====================================================================
Phase 3, adaptive, randomized, placebo-controlled trial in hospitalized adults with mild/moderate or severe COVID-19 (NCT04280705; ACTT-1): Serious adverse events (e.g., cardiac events, respiratory distress or failure, acute kidney injury, hypotension) reported in 21% in remdesivir group and 27% in placebo group; grade 3 or 4 adverse events occurred in 29% in remdesivir group and 33% in placebo group.
Most common nonserious grade 3 or greater adverse events in remdesivir group were anemia or decreased hemoglobin concentrations (8%); acute kidney injury, decreased eGFR or Clcr, or increased Scr (7%); pyrexia (5%); hyperglycemia or increased blood glucose concentrations (4%); and increased ALT and/or AST concentrations (4%); these were reported in 3–9% of patients in placebo group.
==================================================================================
Phase 3, randomized, open-label trial in hospitalized adults with severe COVID-19 (NCT04292899; GS-US-540-5773; SIMPLE-Severe): Adverse events reported in 70 or 74% of patients who received a 5- or 10-day remdesivir regimen, respectively; serious adverse events (e.g., respiratory distress or failure, septic shock) reported in 21 or 35%, respectively, and grade 3 or greater adverse events reported in 30 or 43%, respectively.
Drug discontinued because of adverse events in 4% of patients in 5-day group and 10% of patients in 10-day group. All-cause mortality at day 28 was 10 or 13% in the 5- or 10-day group, respectively.
Most common adverse events overall were nausea (10 or 9%), acute respiratory failure (6 or 11%), increased ALT concentrations (6 or 8%), and constipation (7% in both groups),
Cohort of 53 hospitalized patients in manufacturer's compassionate-use program: Adverse events (e.g., increased hepatic enzymes, diarrhea, rash, renal impairment, hypotension) reported in 60% of patients; serious adverse events (e.g., multiple organ dysfunction syndrome, septic shock, acute kidney injury, hypotension) reported in 23%; drug discontinued because of adverse events in 8% of patients.
=============================================================
.
=============================
The FDA has authorized emergency use of remdesivir only in people with COVID-19 who are in a hospital.
You must remain under the care of a doctor while receiving remdesivir.
What Patients are being told
( CHINA SHARED their RESULTS.. above ) This is what is being shared in this country.
Remdesivir Uses, Side Effects & Warnings - Drugs.com
Physician reviewed remdesivir patient information - includes remdesivir description, dosage and directions.
www.drugs.com
=============================
The FDA has authorized emergency use of remdesivir only in people with COVID-19 who are in a hospital.
You must remain under the care of a doctor while receiving remdesivir.
Remdesivir side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you have:
- nausea, vomiting;
- chills or shivering;
- increased sweating; or
- a light-headed feeling, like you might pass out;
- abnormal liver function tests; or
- pain, swelling, bruising, or bleeding around the IV needle.